Linganisha mbinu

	Kiwango cha Kimataifa cha Tathmini ya Dalili za Miguu Isiyotulia	Kiashirio cha Hali ya Usingizi
Nyanja	Tiba ya Usingizi	Tiba ya Usingizi
Familia	Process / pipeline	Process / pipeline
Mwaka wa asili	2003	2014
Mwanzilishi	Walters, A. S., LeBrocq, C., Dhar, A., et al.	Espie, C. A., Kyle, S. D., Hames, P., et al.
Aina	Clinician-rated; patient-reported symptoms	Self-report
Chanzo asilia	Walters, A. S., LeBrocq, C., Dhar, A., et al. (2003). Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Medicine, 4(2), 121-132.	Espie, C. A., Kyle, S. D., Hames, P., Cbermack, R. A., & Morin, C. M. (2014). A randomized, placebo-controlled trial of online cognitive behavioral therapy for chronic insomnia disorder delivered via a mobile application. Sleep, 37(9), 1553-1563.
Majina mbadala	IRLS, Restless Legs Syndrome Rating Scale	Sleep Condition Indicator, SCI Insomnia Scale
Zinazohusiana	3	3
Muhtasari	The IRLS is a 10-item clinician-administered rating scale designed to assess the severity of symptoms in patients with restless legs syndrome (RLS). Developed and validated by Walters and colleagues in 2003 for the International Restless Legs Syndrome Study Group, it is the most widely used disease-specific severity measure for RLS in clinical practice and research. The scale captures the cardinal features of RLS—nocturnal leg discomfort, urge to move, sleep disruption, and functional impairment—across multiple dimensions.	The Sleep Condition Indicator (SCI) is an 8-item self-report scale designed to assess the severity of insomnia symptoms in adults in a manner closely aligned with DSM-5 diagnostic criteria for insomnia disorder. Developed by Espie and colleagues in 2014, it measures the core features of insomnia: difficulty initiating sleep, difficulty maintaining sleep, early morning awakening, daytime impairment, and associated distress. The SCI is increasingly used in clinical practice and research to screen for insomnia, monitor treatment response, and evaluate cognitive-behavioral therapy efficacy.